Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Machine, Furnitures, Fixtures & OtherOther Gross PP&E Adjustments
Ratios

Spyre Therapeutics (SYRE) Accumulated Depreciation & Amortization (2016 - 2023)

Spyre Therapeutics (SYRE) has disclosed Accumulated Depreciation & Amortization for 9 consecutive years, with $744000.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Accumulated Depreciation & Amortization fell 52.52% year-over-year to $744000.0, compared with a TTM value of $744000.0 through Dec 2023, down 52.52%, and an annual FY2023 reading of $744000.0, down 52.52% over the prior year.
  • Accumulated Depreciation & Amortization was $744000.0 for Q4 2023 at Spyre Therapeutics, down from $1.6 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $2.0 million in Q4 2020 and bottomed at $744000.0 in Q4 2023.
  • Average Accumulated Depreciation & Amortization over 5 years is $1.4 million, with a median of $1.6 million recorded in 2022.
  • The sharpest move saw Accumulated Depreciation & Amortization surged 87.96% in 2020, then plummeted 52.52% in 2023.
  • Year by year, Accumulated Depreciation & Amortization stood at $1.1 million in 2019, then soared by 87.96% to $2.0 million in 2020, then decreased by 20.52% to $1.6 million in 2021, then fell by 0.57% to $1.6 million in 2022, then tumbled by 52.52% to $744000.0 in 2023.
  • Business Quant data shows Accumulated Depreciation & Amortization for SYRE at $744000.0 in Q4 2023, $1.6 million in Q4 2022, and $1.6 million in Q4 2021.